Iovance Biotherapeutics Inc 2LB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if 2LB is a good fit for your portfolio.
News
-
Iovance Biotherapeutics Syas FDA Lifts Partial Clinical Hold on LN-145
-
This biotech ETF sees 'breakout' while U.S. small-cap technology stocks lag
-
Iovance Shares Hits 52-Week High After Offering Pricing, FDA Approvals
-
Iovance Says Amtagvi Gets Accelerated Approval for Advanced Melanoma
-
Iovance stock drops 24% after it halts cancer-drug trial
-
Iovance Shares Fall Premarket As FDA Places Study On Hold After Patient Death
-
ARM's stock rises after IPO, Axcella and Adobe shares slump, and other stocks on the move
-
Iovance Biotherapeutics Shares Rise 12% After Positive Lung Cancer Therapy Trial Data
Trading Information
- Previous Close Price
- $7.92
- Day Range
- $7.68–7.68
- 52-Week Range
- $3.16–43.50
- Bid/Ask
- $7.55 / $7.61
- Market Cap
- $2.15 Bil
- Volume/Avg
- 0 / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1,120.79
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 557
- Website
- https://www.iovance.com
Comparables
Valuation
|
Metric
|
2LB
|
MRSN
|
KURA
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.52 | 9.05 | 3.14 |
Price/Sales | 1,120.79 | 6.46 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
2LB
|
MRSN
|
KURA
|
|---|---|---|---|
Quick Ratio | 4.28 | 3.43 | 16.34 |
Current Ratio | 4.63 | 3.51 | 16.67 |
Interest Coverage | — | −34.91 | −116.04 |
Quick Ratio
2LB
MRSN
KURA
Profitability
|
Metric
|
2LB
|
MRSN
|
KURA
|
|---|---|---|---|
Return on Assets (Normalized) | −47.28% | −41.22% | −28.85% |
Return on Equity (Normalized) | −60.65% | −196.75% | −31.62% |
Return on Invested Capital (Normalized) | −55.60% | −129.55% | −33.98% |
Return on Assets
2LB
MRSN
KURA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Gwfmkghwt | Ylvtq | $635.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jlzjmlrlb | Gzwgqp | $124.1 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Phftcqgw | Vhhmy | $114.2 Bil | |||
| Moderna Inc
MRNA
| Klxtkfzh | Tgmx | $53.7 Bil | |||
| argenx SE ADR
ARGX
| Zgsygwr | Zpt | $23.0 Bil | |||
| BioNTech SE ADR
BNTX
| Pmdngpt | Lslxv | $22.2 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Vmgkkfbh | Pqpnwb | $20.3 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Yvlbppv | Jkrhhrt | $15.9 Bil | |||
| United Therapeutics Corp
UTHR
| Bpkdgtl | Jsqn | $12.8 Bil | |||
| Incyte Corp
INCY
| Hfmgdjnv | Pztffbb | $12.2 Bil |